Posted on 1 Comment

Sibionics vs. Dexcom vs. Libre: CGM Comparison

Dexcom G7 vs. Libre 3 vs. Sibionics GS1

2025 CGM Showdown: Dexcom G7 vs Libre 3 vs Sibionics GS1

Continuous Glucose Monitoring (CGM) has transformed diabetes management from a finger-pricking chore into a real-time data-driven science. In 2025, three standout CGM systems—Dexcom G7, Abbott FreeStyle Libre 3 (and Libre 3 Plus), and Sibionics GS1—are competing fiercely for user preference. But which one truly fits your lifestyle, health needs, and budget?

This blog post breaks down the latest data, clinical research, regulatory milestones, and real-world feedback to help you make an informed decision. Whether you’re tech-savvy, cost-conscious, or simply looking for convenience and safety, we’ve got you covered with deep analysis and practical observations.


🌟 Quick Snapshot: 2025 CGM Landscape

CGM SystemMARD (Adults)Hypo DetectionWear TimeWarm-up & DosingAlertsIntegrationsAvg Cost (Insured)
Dexcom G7 (15d)~8.2%~80%15d + 12h grace~30 min, dose @ ~11.5hPredictive, customPumps, Apple Watch, AID~$89/mo
Libre 3 / 3 Plus~9.2%~73%14-15d, no grace~60 min, dose @ ~12hBasic threshold onlySome (iLet), no Apple Watch~$40/mo
Sibionics GS1~8.83% (high), ~15% in low BG<70%14d, no graceNot specifiedReal-time, fewer optionsRemote view onlyRegion-dependent

🎯 Accuracy Matters: MARD & Hypo Detection

Dexcom G7 stands out as the most accurate CGM in 2025. With a MARD of ~8.2%, it is FDA-cleared for non-adjunctive insulin dosing and includes performance consistency even during hypoglycemia. Its predictive alert engine and rapid sensor response provide an added layer of safety, especially for users with Type 1 diabetes or those using insulin pumps.

Libre 3, while offering a competitive MARD of ~9.2%, tends to underperform slightly in hypoglycemic range detection. However, its real-world readings are remarkably stable and minute-by-minute data gives a higher-resolution glucose trend. Recent studies suggest that Libre 3 performs more consistently during the first 12 hours compared to Dexcom G7, which may have a slight accuracy dip during initial use.

Sibionics GS1, the latest entrant, impresses with a MARD of ~8.83%. However, deeper analysis reveals a concerning ~15% error margin during low-glucose episodes. While it performs well under stable glycemic conditions, it may not be ideal for users at risk of hypoglycemia. This makes it more suitable for Type 2 diabetes users or those using CGM for lifestyle and trend insights rather than critical insulin decision-making.


⏱️ Sensor Wear & Warm-up Times

Dexcom G7 has made a big leap in usability with the 15-day wear time and a 12-hour grace period. This is a major advantage for users who dislike frequent sensor changes. Its 30-minute warm-up is the fastest in the CGM market and provides rapid transition to real-time data collection.

Libre 3 and Libre 3 Plus offer up to 15 days of wear but come without a grace window, which can be disruptive for users needing to maintain continuity in glucose monitoring. Its 60-minute warm-up is longer, and while users can start seeing data sooner, the ability to make insulin dosing decisions is delayed by nearly 12 hours post-insertion.

Sibionics GS1 offers a full 14-day wear time and is factory-calibrated with no fingersticks. However, the lack of published warm-up and grace time data is a downside. User reports suggest that the sensor stabilizes quickly, but further clinical validation is required. In terms of waterproofing, GS1 is rated for immersion up to 1 meter for 1 hour, similar to Dexcom and Libre.


🚨 Alerts, Alarms, and App Functionality

Dexcom G7’s alert system is the most advanced among the three. It includes:

  • “Urgent Low Soon” predictive alert
  • Custom delay-first-high notification
  • Dual alert profiles (e.g., exercise vs sleep)
  • Mute/vibrate override
  • Seamless Apple Watch streaming without a phone

Libre 3 includes basic alerts:

  • Mandatory urgent low glucose alert
  • Optional high/low threshold alerts

However, it lacks predictive notifications, which can be critical for preemptive action in rapidly changing glucose trends. Libre’s app is clean and user-friendly, but is limited in terms of integration and customizability.

Sibionics GS1 offers real-time updates and remote sharing, making it suitable for caregivers. However, it does not currently support customizable or predictive alerting. The app interface is functional and allows for AGP (Ambulatory Glucose Profile) reporting but lacks integrations with wearables or third-party platforms.


⚙️ Real-World Integration & Compatibility

Dexcom G7 is the undisputed leader in terms of ecosystem integration. It connects with:

  • Omnipod 5 (fully automated insulin delivery)
  • Tandem t:slim X2 (Control-IQ algorithm)
  • Beta Bionics iLet (bi-hormonal AID system)
  • Direct-to-watch streaming
  • Apple Health & third-party fitness apps

Libre 3 Plus has made strides by integrating with the iLet system, but still lacks broader compatibility. Abbott is working toward broader AID inclusion but hasn’t matched Dexcom’s ecosystem reach yet.

Sibionics GS1 is still developing its integration strategy. It is a standalone CGM, without current support for insulin pumps or closed-loop systems. It’s ideal for users who want passive glucose tracking and trend insight rather than automated insulin control.


💰 Affordability & Accessibility

  • Dexcom G7 pricing has improved with programs like Simple Start (~$89/month) and expanded insurance coverage. It’s still premium-priced but often covered for Type 1 and insulin-using Type 2 patients.
  • Libre 3 remains the most affordable CGM, especially with Abbott’s pricing structure and global reach. In many countries, it’s free for users with government or private insurance. Out-of-pocket costs are significantly lower (~$40/month).
  • Sibionics GS1 targets cost-sensitive markets like China, UAE, and parts of Southeast Asia. While not yet FDA-approved, it is CE-marked and available for direct purchase online. It offers a viable low-cost alternative but lacks institutional insurance backing in most Western countries.

🔍 2025 Clinical & Regulatory Milestones

  • Dexcom G7: Gained 15-day FDA clearance in March 2024, extending wear and improving MARD to 8.0%. Widely available in US/EU, with real-world MARD validated across various age groups.
  • Libre 3 Plus: Expanded availability in EU and select US states. Clinical trials ongoing for broader AID compatibility. Studies show early-day stability is better than Dexcom G7.
  • Sibionics GS1: Gained CE-mark in 2023, and UAE approval in 2024. Multi-center trial results published, but limited performance data for hypoglycemia. MARD values promising, but needs stronger low-glucose validation.

🤔 So, Which One Is Right for You?

Choose Dexcom G7 if:

  • You require integration with an insulin pump or closed-loop system.
  • You rely on predictive alerts to avoid lows or highs.
  • You value advanced app features and wearable syncing.

Choose Libre 3 / 3 Plus if:

  • You are cost-conscious and value ease of use.
  • You’re comfortable with fewer alert customizations.
  • You want a minimal, slim sensor with automatic data sync.

Choose Sibionics GS1 if:

  • You live in a region where it is supported (e.g., China, UAE).
  • You are a Type 2 or stable Type 1 user not prone to hypoglycemia.
  • You’re seeking a low-cost, factory-calibrated CGM with basic functionality.

✅ Final Thoughts

In 2025, CGM systems are smarter, more accessible, and more personalized than ever. Dexcom G7 leads in precision, safety, and ecosystem depth. Libre 3 offers an excellent middle ground for cost and performance. Sibionics GS1 brings new competition to emerging markets but may need more time to build trust in critical scenarios.

Whichever CGM you choose, ensure it aligns with your clinical needs, lifestyle preferences, and regional availability. Don’t hesitate to consult your endocrinologist for guidance.

Stay empowered. Stay connected. Stay in control.

📚 Frequently Asked Questions (FAQs)

1. What is the most accurate CGM available in 2025?
Dexcom G7 currently leads in accuracy, especially in hypoglycemic ranges, with a MARD of ~8.2% and even lower (~8.0%) in its new 15-day version.

2. Which CGM is the most affordable?
Libre 3 / 3 Plus is the most budget-friendly option, with an average insured cost of ~$40/month. It’s widely accessible and often fully covered by public insurance in many countries.

3. Can I use Sibionics GS1 with an insulin pump?
No, Sibionics GS1 is currently not compatible with insulin pumps or closed-loop systems. It functions as a standalone CGM for manual glucose monitoring.

4. How long can each CGM be worn?

  • Dexcom G7: 15 days + 12-hour grace period
  • Libre 3/3 Plus: 14–15 days (no grace period)
  • Sibionics GS1: 14 days (no published grace period)

5. Which CGMs support predictive low glucose alerts?
Only Dexcom G7 supports predictive alerts like “Urgent Low Soon,” which notify users before a hypoglycemic event occurs.

6. Are these CGMs approved for non-adjunctive insulin dosing?
Yes, both Dexcom G7 and Libre 3/3 Plus are FDA-approved for insulin dosing. Sibionics GS1 has CE-mark but lacks FDA clearance and insulin dosing approval.

7. Which CGM is best for smartwatch integration?
Dexcom G7 allows direct data streaming to Apple Watch without needing your phone. Libre and Sibionics do not currently support smartwatch connectivity.

8. How long do I need to wait before using a CGM for dosing after inserting it?

  • Dexcom G7: ~11.5 hours after insertion
  • Libre 3: ~12 hours
  • Sibionics GS1: No clear guideline published; likely longer due to warm-up variability

9. Is there a CGM suitable for non-insulin users or those with Type 2 diabetes?
Yes, Libre 3 and Sibionics GS1 are excellent options for Type 2 or lifestyle monitoring. Dexcom G7 is ideal for insulin users but also supports Type 2 monitoring.

10. Where is Sibionics GS1 available?
As of 2025, it is available in China, UAE, and some parts of Europe. It’s CE-marked but not FDA-approved, so availability is limited in North America.

Posted on 1 Comment

Dexcom G6 vs. G7: A Comprehensive Comparison

As technology continues to advance, the field of continuous glucose monitoring (CGM) is not far behind. Dexcom, a leading player in the CGM market, has introduced its latest models, the Dexcom G6 and G7. In this post, we will conduct an in-depth comparison of these two models to help you make an informed decision about which one is better suited for your needs.

Dexcom G6 vs. G7: Which is the Better Choice?

1. Accuracy and Sensor Performance: The accuracy of a CGM system is of paramount importance for effective diabetes management. The Dexcom G7 boasts an improved sensor design that offers greater accuracy and reliability compared to the G6. This enhanced sensor performance translates to more precise glucose readings and better decision-making.

2. Wear Duration: The Dexcom G6 sensor is designed for a wear duration of up to 10 days. On the other hand, the G7 takes it a step further with a wear duration of up to 14 days. This longer wear duration can lead to fewer sensor insertions and increased convenience.

Dexcom G7 Review | One Mystery Part Changes Everything! Youtube video by Diabetes Daily Digest

3. Insertion Process: The insertion process is a critical factor in user experience. The Dexcom G7 introduces a one-button insertion process that is not only simpler but also minimizes discomfort. This design enhancement makes the G7 more user-friendly, especially for those new to CGM technology.

4. Size and Profile: The Dexcom G7 sensor is smaller and more discreet compared to its predecessor. The reduced profile contributes to greater comfort and less visibility when worn. This improvement is particularly appreciated by users who value a discreet appearance.

5. Transmitter Design: The Dexcom G6 and G7 transmitters have undergone a redesign to be more compact and ergonomic. The G7 transmitter, in particular, features a sleeker design that is less obtrusive during wear. This is a significant consideration for users who prefer a low-profile look.

6. Smart Device Integration: Both the Dexcom G6 and G7 offer seamless integration with compatible smart devices, allowing users to receive real-time glucose data on their smartphones. The G7’s Bluetooth capabilities ensure a strong and reliable connection for uninterrupted data transmission.

7. Availability and Transition: While the Dexcom G7 represents an upgrade in various aspects, availability might vary depending on your location and healthcare provider. The transition from G6 to G7 involves adapting to the enhanced features and benefits of the newer model.

Frequently Asked Questions (FAQ) about Dexcom G6 and G7 CGM

Q1: What are the key differences between Dexcom G6 and G7? Dexcom G6 and G7 differ in accuracy, wear duration, insertion process, size, transmitter design, and smart device integration. G7 offers improved accuracy, a longer 14-day wear duration, one-button insertion, a smaller profile, and enhanced transmitter design.

Q2: Is the Dexcom G7 more accurate than the G6? Yes, the Dexcom G7 is designed to offer improved accuracy compared to the G6, leading to more precise glucose readings for better diabetes management.

Q3: How long can I wear a Dexcom G7 sensor? The Dexcom G7 sensor can be worn for up to 14 days, providing an extended wear duration compared to the G6.

Q4: What is the insertion process like for the Dexcom G7? The Dexcom G7 features a one-button insertion process, simplifying the experience and minimizing discomfort during sensor placement.

Q5: Is the Dexcom G7 sensor smaller and more discreet? Yes, the Dexcom G7 sensor is designed to be smaller and more discreet, offering greater comfort and a less noticeable appearance when worn.

Q6: How is the transmitter design improved in the G7? The Dexcom G7 transmitter features a more compact and ergonomic design, contributing to a more comfortable and discreet wear experience.

Q7: Can I receive glucose data on my smartphone with both models? Yes, both Dexcom G6 and G7 offer seamless integration with compatible smart devices, allowing real-time glucose data to be accessed on smartphones.

Q8: Which model is right for me, G6 or G7? The choice between Dexcom G6 and G7 depends on factors like accuracy, wear duration, insertion process, and individual preferences. Consider your needs and the availability of each model in your region.

Q9: Is the transition from G6 to G7 easy? Transitioning from Dexcom G6 to G7 involves adapting to the enhanced features of the newer model. Consult your healthcare provider for guidance on the transition process.

Q10: How can I get Dexcom G6 or G7? Dexcom CGM systems are available through healthcare providers. Consult your healthcare team to determine the availability of G6 and G7 in your region.

Q11: Are there any other considerations when choosing between G6 and G7? Other factors to consider include your healthcare provider’s recommendation, insurance coverage, and the level of technology integration you prefer.

Conclusion

In the debate of Dexcom G6 vs. G7, both models bring valuable features to the table. The Dexcom G7 shines with its improved accuracy, longer wear duration, simplified insertion process, and discreet profile. However, the decision ultimately depends on your individual preferences, needs, and the availability of these models in your region.

By understanding the differences between the Dexcom G6 and G7, you can make an informed choice that aligns with your diabetes management goals. Always consult with your healthcare provider before making any changes to your CGM system.

Feel free to share your thoughts and experiences with the Dexcom G6 and G7 in the comments below. Your insights can provide valuable perspectives to others considering these advanced CGM options.

Blog Tags: Dexcom, Dexcom G6, Dexcom G7, continuous glucose monitoring, CGM technology, diabetes management, glucose monitoring devices, G6 vs G7, CGM comparison, diabetes technology, wear duration, accuracy, smart device integration, healthcare technology